Skip to main content
Yabao Pharmaceutical Group Co.,Ltd logo

Yabao Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 600351 ISIN · CNE000001CM5 LEI · 65560071PKRS4UHMVU53 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,362 across all filing types
Latest filing 2021-01-18 Earnings Release
Country CN China
Listing Shanghai Stock Exchange 600351

About Yabao Pharmaceutical Group Co.,Ltd

http://www.yabao.com.cn

Yabao Pharmaceutical Group Co.,Ltd. focuses on the research, development, manufacturing, and commercialization of pharmaceutical products. The company maintains a specialized portfolio across therapeutic areas including pediatrics, cardiovascular health, and endocrinology. Key offerings include traditional Chinese medicines, chemical drugs, and innovative transdermal patches, such as the Dinggui Erqi Patch. The organization operates integrated production bases and research facilities dedicated to advancing drug delivery systems and biotechnological applications. Its business model emphasizes the modernization of traditional therapies alongside the development of conventional pharmaceuticals to address diverse clinical needs.

Recent filings

Filing Released Lang Actions
2020年年度业绩预增公告
Earnings Release Classification · 95% confidence The document is titled as a 2020 annual performance forecast announcement by 亚宝药业集团股份有限公司. It provides preliminary estimated net profit figures for the full year 2020, comparing them to the prior year, and explicitly states that the forecasted results are unaudited and preliminary. The document length is short (1239 characters) and it does not contain actual audited financial statements or detailed financial analysis. It is a forward-looking earnings forecast rather than a full annual report or earnings release. The document also states that the final audited 2020 annual report will be published later. This type of document is best classified as an Earnings Release (ER) because it announces key financial results highlights for a fiscal year, even though it is a forecast rather than final results. It is not a full Annual Report (10-K) or Interim Report (IR) because it lacks comprehensive financial statements and analysis. It is not a Report Publication Announcement (RPA) because it contains substantive financial forecast data rather than just announcing a report's release. FY 2020
2021-01-18 Chinese
关于股东减持比例达到1%的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a public announcement from a company disclosing a shareholder's reduction in shareholding by more than 1%. It details the number of shares reduced, the percentage change in ownership, and confirms that the change does not affect control or trigger a mandatory offer. The document is titled as a "提示性公告" (prompting announcement) about shareholder reduction and includes detailed shareholding percentages before and after the transaction. There is no financial data, earnings information, or management discussion. This type of document fits the definition of a Major Shareholding Notification (MRQ), which reports changes in significant share ownership levels crossing thresholds.
2020-12-22 Chinese
关于受让武汉健民资本合伙企业（有限合伙）财产份额的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement by 亚宝药业集团股份有限公司 regarding the acquisition of a 40.68% property share in 武汉健民资本合伙企业 (a limited partnership) from 浙江华方资产管理有限公司. It includes extensive information about the transaction, parties involved, financial data of the entities, legal and tax considerations, and the strategic purpose and risks of the transaction. The document is a formal announcement of a capital transaction involving share acquisition in a partnership, with no indication of it being a full financial report, audit report, or other types of filings. It is not a report publication announcement since it contains substantive details about the transaction itself. The content fits best under Capital/Financing Update (CAP) as it relates to company fundraising, financing activities, or capital structure changes.
2020-12-18 Chinese
股东集中竞价减持股份进展公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement regarding the progress of a shareholder's concentrated share reduction plan. It details the shareholding structure, the amount and percentage of shares reduced, the timeline, and the impact on company control. It does not contain financial statements or detailed financial analysis but focuses on shareholding changes and compliance with regulatory requirements. The document length is 2295 characters, which is relatively short and typical for a regulatory announcement. This fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels. Therefore, the appropriate classification is MRQ.
2020-11-05 Chinese
关于公司药品通过仿制药一致性评价的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by 亚宝药业集团股份有限公司 regarding the approval of a pharmaceutical product (马来酸依那普利片) passing a generic drug consistency evaluation by the National Medical Products Administration of China. It includes details about the drug, regulatory approval, company R&D expenses, and a risk warning to investors. The document is short (1141 characters) and serves as an official announcement of regulatory approval rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or management commentary. It is not a report publication announcement since it contains substantive content about the approval and implications. The document fits best under Regulatory Filings (RNS) as a general regulatory announcement about product approval and related corporate information that does not fit other specific categories.
2020-10-27 Chinese
2020年第三季度报告正文
Interim / Quarterly Report Classification · 95% confidence The document is titled '2020 年第三季度报告' which translates to '2020 Third Quarter Report'. It contains detailed financial data including total assets, net assets, operating income, net profit, earnings per share, and cash flow statements for the third quarter of 2020. The report includes comparative figures from the previous year and explanations for significant changes in financial statement items. The document length is 7146 characters, which is substantial and contains actual financial data and analysis, not just an announcement or certification. The content matches the definition of an Interim / Quarterly Report (IR), as it covers a period shorter than a full fiscal year with substantive financial data and analysis. Therefore, the correct classification is IR with high confidence. Q3 2020
2020-10-23 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.